Shots:   

• The CHMP has granted a positive opinion to DRL_RI (Ituxredi), a biosimilar of MabThera (rituximab) 
• The approval, if granted, would be applicable across the whole EU plus Norway, Iceland & Liechtenstein. A separate MAA will be submitted to the MHRA as per reliance route under the IRP 
• Ituxredi (CD20 directed cytolytic Ab) is for the treatment of Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukaemia (CLL), Rheumatoid Arthritis (RA), Granulomatosis with Polyangiitis (GPA) & Microscopic Polyangiitis (MPA) as well as Pemphigus Vulgaris (PV) 

Ref: Alvotech | Image: Alvotech

Related News:- Alvotech Reports Data from the Trial of AVT03 (Biosimilar, Prolia and Xgeva) for Skeletal Diseases

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com